Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

To investigate the efficacy of resistance exercise on symptoms of vestibular migraine (VM) among migraine patients, a total of 385 VM patients were recruited, among whom 312 were eligible to participate in the current study. Patients were randomly allocated into either resistance exercise or relaxation control groups, and received respective interventions two times per week for 12 weeks. Patients were followed up at two and four months, respectively, to evaluate treatment effects. Primary outcomes included Dizziness Handicap Inventory (DHI), the number of vertiginous attacks in the previous week and Vertigo Severity Scale (VSS). Secondary endpoints included depression and anxiety symptoms, which were measured using the scores of the Beck Anxiety Inventory (BAI) and the Beck Depression Inventory (BDI). Serum concentrations of pro-inflammatory cytokines, including tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ), were also assessed. Resistance exercise was slightly more pronounced in alleviating VM symptoms than relaxation control at two-month follow-up. While at four-month follow-up, the extents of the symptom attenuation were obviously better in the resistance exercise group than the relaxation control, in terms of VSS and DHI scores, as well as BDI and BAI scores. Serum levels of both TNF-α and IFN-γ were also significantly lower in patients in the resistance group than those in the relaxation control group. Our study favors an exercise-oriented treatment scheme in rehabilitating therapy for patients suffering from VM, and sheds light on the molecular mechanism potentially involving TNF-α and IFN-γ related inflammation pathways. Copyright © 2021 Elsevier Masson SAS. All rights reserved.


L Sun, G Li, F Liu, Y Wang, L Zhang, C Minoret. Resistance exercise relieves symptoms of vestibular migraine patients with MRI diagnosis: A randomized parallel-controlled single-blind clinical trial. Revue neurologique. 2022 Apr;178(4):370-376

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 34598780

View Full Text